Obizur
Obizur
| Product Specs | Obizur |
|---|---|
| Manufacturer Name | Takeda |
| Indications | OBIZUR, Antihemophilic Factor (Recombinant), Porcine Sequence, is an antihemophilic factor indicated for the on-demand treatment and control of bleeding episodes in adults with acquired hemophilia A. |
| Contraindications | Do not use in patients who have had life-threatening hypersensitivity reactions to OBIZUR or its components, including hamster protein. |
| Manufacturing Methods | Genetically engineered baby hamster kidney (BHK) cell line which secretes rpFVIII into the cell culture medium |
| Viral Safety Process | Chromatography, solvent/detergent treatment, nanofiltration |
| Route of Administration | Intravenous |
| Product Half-Life | Range 2.6 to 28.6 hours |
| Shelf Life | Listed on label |
| Storage Requirements |
|
| Available Formulations | When reconstituted with the diluent, the product contains the following components per mL: 8.8 mg sodium chloride, 0.04 mg Tris-base, 0.73 mg Tris-HCl, 1.47 mg trisodium citrate dehydrate, 0.15 mg calcium chloride dehydrate, 1.9 mg sucrose, and 0.05 mg polysorbate 80 |
Return to Manufacturer Name listing Return to Factor Type listing